Table 2 Baseline characteristics overall and by induction immunosuppression CTP
All n = 41 | CYC n = 24 | MMF n = 17 | p-value | |
|---|---|---|---|---|
Demographics | ||||
Age at enrollment in years, mean (SD) | 14.7 (2.8) | 15.2 (2.9) | 14 (2.6) | 0.146 |
Age at SLE diagnosis in years, mean (SD) | 13.8 (2.8) | 13.8 (2.9) | 13.7 (2.7) | 0.832 |
SLE duration in weeks, median (IQR) | 6 (1–73) | 14 (3, 120) | 5 (1, 10) | 0.130 |
Female, n (%) | 34 (83) | 18 (75) | 16 (94) | 0.109 |
Race, n (%) | 0.889 | |||
White | 16 (39) | 10 (42) | 6 (35) | |
Black or African American | 11 (27) | 6 (25) | 5 (29) | |
Asian or Pacific Islander | 6 (15) | 4 (17) | 2 (12) | |
Other | 8 (19) | 4 (17) | 4 (24) | |
Hispanic ethnicity, n (%) | 11 (27) | 6 (25) | 5 (29) | 0.753 |
Parental Income in US $/year, n/total (%) | 0.798 | |||
< 25,000 | 6/26 (23) | 4/15 (27) | 2/11 (18) | |
25–49,999 | 8/26 (31) | 3/15 (20) | 5/11 (45) | |
50–74,999 | 2/26 (8) | 1/15 (7) | 1/11 (9) | |
75–99,999 | 6/26 (23) | 4/15 (27) | 2/11 (18) | |
100–150,000 | 2/26 (8) | 2/15 (13) | 0/11 | |
> 150,000 | 2/26 (8) | 1/15 (7) | 1/11 (9) | |
Insured, n (%) | 36 (88) | 20 (83) | 16 (94) | 0.382 |
Clinical and laboratory characteristics | ||||
Lupus nephritis class, n (%) | 0.005 | |||
ISN-RPS Class III, n (%) | 16 (39) | 5 (21) | 11 (65) | |
ISN-RPS Class IV, n (%) | 25 (61) | 19 (79) | 6 (35) | |
Concurrent ISN-RPS Class V LN, n (%) | 14 (34) | 6 (25) | 8 (47) | 0.142 |
GFR in ml/min/1.73 m2, median (IQR)a | 94 (70–107) | 93 (79–107) | 95 (67–123) | 0.864 |
Proteinuria in mg pr/mg cr, median (IQR)b | 1.9 (1.1–4.7) | 1.9 (1.3–4.6) | 1.8 (0.8–4.7) | 0.554 |
Hematuria present, n/total (%) | 29/40 (73) | 22/23 (96) | 7/15 (47) | 0.001 |
Hypertension, n/total (%)c | 23/37 (62) | 13/20 (65) | 10/17 (59) | 0.699 |
ESR in mm/hr., mean (SD) | 50 (33) | 44 (27) | 60 (41) | 0.304 |
Complement factor 3, median (IQR) | 51 (39–75) | 51 (39–71) | 55 (31–98) | 0.685 |
Complement factor 4, median (IQR) | 6 (4–8) | 6 (3–8) | 6 (4–14) | 0.578 |
Elevated dsDNA, n/total (%) | 32/36 (89) | 20/22 (91) | 12/14 (86) | 0.629 |
Antiphospholipid antibody present, n/total (%) | 24/40 (60) | 14/24 (58) | 10/16 (63) | 0.792 |
SLEDAI-2 K, median (IQR) | 12 (8–20) | 16 (10–20) | 12 (6–22) | 0.458 |
PGA, scale 0–10, median (IQR) | 5 (3–6) | 5 (3–6) | 6 (2–6) | 0.707 |
SLICC Damage Index, n/total (%) | 0.677 | |||
Total Score 0 | 30/37 (81) | 17/22 (77) | 13/15 (87) | |
Total Score 1 | 7/37 (19) | 5/22 (23) | 2/15 (13) | |